AB Science announces a slight delay in the publication of its 2024 half-year financial report
30 Setembro 2024 - 1:33PM
UK Regulatory
AB Science announces a slight delay in the publication of its 2024
half-year financial report
PRESS RELEASE
AB SCIENCE ANNOUNCES A SLIGHT DELAY IN
THE PUBLICATION OF ITS 2024 HALF-YEAR FINANCIAL REPORT
THE COMPANY WILL PUBLISH ITS HALF-YEAR
FINANCIAL REPORT FOR 2024 ON OCTOBER 7, 2024
Paris, September 30 2024, 6.30pm
CET
AB Science SA (Euronext -
FR0010557264 - AB) today announced that it has postponed the
publication of its financial report for the first half of 2024,
initially scheduled for 30 September 2024, to give the auditors
time to complete their audit work.
The Company will publish its financial report
for the first half of 2024 on Monday 7 October 2024, after
trading.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company
specializing in the research, development and commercialization of
protein kinase inhibitors (PKIs), a class of targeted proteins
whose action are key in signaling pathways within cells. Our
programs target only diseases with high unmet medical needs, often
lethal with short term survival or rare or refractory to previous
line of treatment.
AB Science has developed a proprietary portfolio
of molecules and the Company’s lead compound, masitinib, has
already been registered for veterinary medicine and is developed in
human medicine in oncology, neurological diseases, inflammatory
diseases and viral diseases. The company is headquartered in Paris,
France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science’s
website: www.ab-science.com.
Forward-looking Statements - AB
Science
This press release contains forward-looking statements. These
statements are not historical facts. These statements include
projections and estimates as well as the assumptions on which they
are based, statements based on projects, objectives, intentions and
expectations regarding financial results, events, operations,
future services, product development and their potential or future
performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB Science
Financial Communication & Media Relations
investors@ab-science.com
- CP Décalage Publication Comptes 2024 S1 VEng VF
Ab Science (LSE:0Q77)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Ab Science (LSE:0Q77)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
